Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy

Immune checkpoint pathways active in Acute Myeloid Leukemia (AML) patients, especially during the course of remission induction chemotherapy, have not been well studied. Although dominant in mediating T cell dysfunction in cancer, it is now well-accepted that interruption of PD-1/PD-L1 axes alone do...

Descripción completa

Detalles Bibliográficos
Autores principales: Dama, Paola, Tang, Marshall, Fulton, Noreen, Kline, Justin, Liu, Hongtao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6621946/
https://www.ncbi.nlm.nih.gov/pubmed/31291985
http://dx.doi.org/10.1186/s40425-019-0611-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6621946/
https://www.ncbi.nlm.nih.gov/pubmed/31291985
http://dx.doi.org/10.1186/s40425-019-0611-3

Ejemplares similares